About this Research Topic
Treatment of ovarian cancer (OC) usually involves a combination of surgery and platinum-based chemotherapy (e.g. cisplatin and paclitaxel). However, OC remains the most lethal gynecologic malignancy worldwide, probably due to late diagnosis, chemoresistance, and ineffective treatment. OC tumorigenesis and resistance to treatment are affected by different factors including angiogenesis, extracellular matrix, cancer-associated fibroblasts, and immune suppression in the tumor microenvironment (TME). Several revolutionary treatment options are rapidly being developed, such as targeted therapy, immune checkpoint inhibitors (ICIs), and chimeric antigen receptor (CAR)-T cells. At this point, further studies uncovering the mechanisms driving tumorigenesis and chemoresistance in OC as well as innovative therapeutic strategies for OC treatment are urgently needed.
OC has the highest mortality rate among gynecological malignancies, because most patients present advanced or metastatic tumors at the time of diagnosis, and approximately 75% of patients experience relapse following treatment. In order to improve overall survival for OC patients, some critical problems in OC research and treatment will need to be addressed. This is what we aim to do in this Research Topic. Areas of interest include: (1) The potential mechanisms of chemoresistance - how does the TME influence OC growth and resistance to treatment? (2) The influence of stroma and cell subsets on immunity and therapeutic efficacy in the OC-TME (3) Novel therapeutic strategies to target OC, such as targeted therapy, immunotherapy, gene- and cell- therapy.
This Research Topic welcomes original research, (mini-) reviews, and opinion pieces that offer insights into the mechanisms driving tumorigenesis and chemoresistance in OC and have a translational impact on the personal, clinical, and societal problems posed by OC. Areas to be covered in this Research Topic will include, but are not limited to:
• The mechanism of chemoresistance following chemotherapy in OC.
• Tumorigenesis and tumor biology underlying OC growth.
• Immunosuppressive phenomena in the OC-TME.
• Stroma components and cell subsets in the OC-TME.
• Advanced therapeutic strategies for OC treatment.
• Targeting OC by targeted therapy and Immunotherapy.
• In vitro and in vivo models for the investigation of OC.
OC has the highest mortality rate among gynecological malignancies, because most patients present advanced or metastatic tumors at the time of diagnosis, and approximately 75% of patients experience relapse following treatment. In order to improve overall survival for OC patients, some critical problems in OC research and treatment will need to be addressed. This is what we aim to do in this Research Topic. Areas of interest include: (1) The potential mechanisms of chemoresistance - how does the TME influence OC growth and resistance to treatment? (2) The influence of stroma and cell subsets on immunity and therapeutic efficacy in the OC-TME (3) Novel therapeutic strategies to target OC, such as targeted therapy, immunotherapy, gene- and cell- therapy.
This Research Topic welcomes original research, (mini-) reviews, and opinion pieces that offer insights into the mechanisms driving tumorigenesis and chemoresistance in OC and have a translational impact on the personal, clinical, and societal problems posed by OC. Areas to be covered in this Research Topic will include, but are not limited to:
• The mechanism of chemoresistance following chemotherapy in OC.
• Tumorigenesis and tumor biology underlying OC growth.
• Immunosuppressive phenomena in the OC-TME.
• Stroma components and cell subsets in the OC-TME.
• Advanced therapeutic strategies for OC treatment.
• Targeting OC by targeted therapy and Immunotherapy.
• In vitro and in vivo models for the investigation of OC.
Keywords: Ovarian Cancer (OC), Tumorigenesis, Chemoresistance, Immunosuppression, Tumor microenvironment (TME), Immunotherapy, Targeted therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
